ES2112340T3 - Proteinas mutantes de il-4 humana. - Google Patents

Proteinas mutantes de il-4 humana.

Info

Publication number
ES2112340T3
ES2112340T3 ES92923502T ES92923502T ES2112340T3 ES 2112340 T3 ES2112340 T3 ES 2112340T3 ES 92923502 T ES92923502 T ES 92923502T ES 92923502 T ES92923502 T ES 92923502T ES 2112340 T3 ES2112340 T3 ES 2112340T3
Authority
ES
Spain
Prior art keywords
pct
date
human
mutant proteins
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92923502T
Other languages
English (en)
Other versions
ES2112340T5 (es
Inventor
Walter Prof Dr Sebald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6444719&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2112340(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer AG filed Critical Bayer AG
Publication of ES2112340T3 publication Critical patent/ES2112340T3/es
Application granted granted Critical
Publication of ES2112340T5 publication Critical patent/ES2112340T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE DESCRIBEN AGENTES TERAPEUTICOS CARACTERIZADOS POR CONTENER PROTEINAS HIL-4 MUTANTES, ANTAGONISTAS O PARCIALMENTE ANTAGONISTAS DE LA INTERLEUCINA-4 HUMANA Y UN PROCESO PARA SU PRODUCCION.
ES92923502T 1991-11-13 1992-11-13 Proteinas mutantes de il-4 humana. Expired - Lifetime ES2112340T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4137333 1991-11-13
DE4137333A DE4137333A1 (de) 1991-11-13 1991-11-13 Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung

Publications (2)

Publication Number Publication Date
ES2112340T3 true ES2112340T3 (es) 1998-04-01
ES2112340T5 ES2112340T5 (es) 2005-10-16

Family

ID=6444719

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92923502T Expired - Lifetime ES2112340T5 (es) 1991-11-13 1992-11-13 Proteinas mutantes de il-4 humana.

Country Status (16)

Country Link
US (1) US5723118A (es)
EP (1) EP0613499B2 (es)
JP (2) JP3470970B2 (es)
KR (1) KR100276410B1 (es)
AT (1) ATE163196T1 (es)
AU (1) AU671960B2 (es)
CA (1) CA2123315C (es)
CZ (1) CZ283467B6 (es)
DE (2) DE4137333A1 (es)
DK (1) DK0613499T4 (es)
ES (1) ES2112340T5 (es)
GR (1) GR3026600T3 (es)
HU (1) HU217326B (es)
NO (1) NO312707B1 (es)
SK (1) SK280114B6 (es)
WO (1) WO1993010235A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
GB9415379D0 (en) * 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
CZ25697A3 (en) * 1994-07-29 1997-09-17 Smithkline Beecham Plc Novel compounds
US6335426B1 (en) 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
US5986059A (en) * 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
IL126995A0 (en) * 1996-06-14 1999-09-22 Bayer Ag T-cell selective interleukin-4 agonists
MY124565A (en) * 1996-07-19 2006-06-30 Bayer Corp High-affinity interleukin-4-muteins
US6180108B1 (en) * 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus
DE10022258A1 (de) 2000-05-08 2001-11-15 Bayer Ag Reinigung von Proteineinschlusskörpern durch Querstrom-Mikrofiltration
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
EP1314739A1 (en) 2001-11-22 2003-05-28 Bayer Ag Process for renaturation of recombinant, disulfide containing proteins at high protein concentrations in the presence of amines
EP1382614A1 (en) * 2002-07-15 2004-01-21 Bayer HealthCare AG Process for the purification of interleukin-4 and its muteins
US7635754B2 (en) * 2004-09-22 2009-12-22 Aerovance, Inc. Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
US20070009479A1 (en) * 2005-06-17 2007-01-11 Aerovance, Inc. Methods for treating dermatitis using mutant human IL-4 compositions
WO2007147600A2 (en) * 2006-06-21 2007-12-27 Apogenix Gmbh Differential il-4 and/or il-10 cytokine expression in human cancer
AU2007271349A1 (en) * 2006-07-06 2008-01-10 Apogenix Gmbh Human IL-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy
EP2596802A1 (en) 2011-11-23 2013-05-29 PLS-Design GmbH Pharmaceutical composition for treatment of allergic reactions
EP2674168A1 (en) 2012-06-14 2013-12-18 PLS-Design GmbH Modulation of effector T cell responses by local depletion of complement component C3

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
EP0327283B1 (en) * 1988-02-02 1993-08-18 Schering Biotech Corporation Method of reducing immunoglobulin e responses
US5188827A (en) * 1989-12-18 1993-02-23 Schering Corporation Use of interleukin-4- for lowering blood-cholesterol levels

Also Published As

Publication number Publication date
HU9401369D0 (en) 1994-08-29
JPH07501522A (ja) 1995-02-16
CA2123315C (en) 2003-06-17
JP3470970B2 (ja) 2003-11-25
US5723118A (en) 1998-03-03
AU2928292A (en) 1993-06-15
SK55494A3 (en) 1994-12-07
NO941681D0 (no) 1994-05-06
EP0613499B2 (de) 2005-03-30
HU217326B (hu) 1999-12-28
EP0613499B1 (de) 1998-02-11
HUT66826A (en) 1995-01-30
DE4137333A1 (de) 1993-05-19
SK280114B6 (sk) 1999-08-06
WO1993010235A1 (de) 1993-05-27
DK0613499T4 (da) 2005-04-18
ATE163196T1 (de) 1998-02-15
CZ118594A3 (en) 1994-12-15
DK0613499T3 (da) 1998-09-23
GR3026600T3 (en) 1998-07-31
NO312707B1 (no) 2002-06-24
AU671960B2 (en) 1996-09-19
JP2003174894A (ja) 2003-06-24
CZ283467B6 (cs) 1998-04-15
KR100276410B1 (ko) 2000-12-15
EP0613499A1 (de) 1994-09-07
DE59209196D1 (de) 1998-03-19
CA2123315A1 (en) 1993-05-27
ES2112340T5 (es) 2005-10-16
NO941681L (no) 1994-05-06

Similar Documents

Publication Publication Date Title
ATE163196T1 (de) Menschliche il-4 mutantenproteine
DE59507920D1 (de) NEUE hIL-4-MUTANTENPROTEINE ALS ANTAGONISTEN ODER PARTIELLE AGONISTEN DES HUMANEN INTERLEUKIN 4
KR950700333A (ko) 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로부터의 제조 방법(improved alpha interferon composition and method for its production from human peripheral blood leukocytes)
KR960701051A (ko) 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
DK46789D0 (da) 3-indolpyrodruesyrederivater og farmaceutisk anvendelse deraf
DE69226649D1 (de) Analoge des menschlichen Interleukin-8.
ES2133329T3 (es) Variantes de il-3 humana.
ES2084149T3 (es) Conjugados de hirudinpolialquilenglicol.
ATE141616T1 (de) Neue peptide (didemnine), ihre herstellung und verwendung
DK0649433T3 (da) Antigeniske regioner fra komplekser af tumorfrigivne partikler (TLP) og antistoffer mod sådanne.
MX9803791A (es) Intermediarios novedosos y su uso para preparar bisindolilmaleimidas n,n'-puenteadas.
MX9206339A (es) Nueva proteina inhibidora de trombina a partir de chinches de monte
SE8501202D0 (sv) Human intestinal hormone and its use
NO305799B1 (no) Nye kinolinderivater, farmas°ytiske preparater inneholdende slike derivater, deres anvendelse samt mellomprodukter
PL309339A1 (en) Novel triazoquinazolines, methods of obtaining them and their application
DE69836226D1 (de) Ifn rezeptor 1 bindende proteine, dafür kodierende dna und verfahren zur regulierung der zellulären antwort auf interferone
MX9205978A (es) Nuevas proteinas inhibidoras de trombina de garrapatas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 613499

Country of ref document: ES